Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

DCC reports operating profit growth as it focuses on energy

(Sharecast News) - DCC reported a 4.9% rise in total adjusted operating profit to £703.6m on a constant currency basis for the year to 31 March on Tuesday, driven by 8.5% growth in its energy division. The FTSE 100 group announced plans to return £800m to shareholders following the agreed sale of DCC Healthcare for £1.05bn, starting with a £100m share buyback programme.

Free cash flow stood at £588.8m with a conversion rate of 84%, while adjusted earnings per share rose 5.2% on a constant currency basis to 470.2p.

The annual dividend was raised by 5% to 206.4p, marking the company's 31st consecutive year of dividend growth.

DCC said it was simplifying its structure to focus on energy, having exited lower-returning operations in Hong Kong and Macau and made targeted acquisitions in Europe aligned with its cleaner energy strategy.

It said it expected good profit growth in the year ahead from continuing operations, supported by further strategic and development progress.

"We are pleased to report that we delivered another year of good growth, while making strategic progress to simplify the group to focus on our opportunity in energy," said chief executive officer Donal Murphy.

"Our sale of DCC Healthcare enables a material return of capital to shareholders.

"We will focus our efforts on energy, our largest and highest-returning business; we are energised about the future."

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.